Prorenin Receptor Blockade Reverses Diabetic Glomerulosclerosis in Rats
Activationof prorenin by the prorenin/renin receptor has been shown toplay a role in the development of diabetic nephropathy in rats,but its involvement in renal progression is unknown. Dr. Takahashiand colleagues report that glomerulosclerosis and proteinuriaregress in diabetic rats treated with the prorenin receptorblocker, whereas angiotensin-converting enzyme inhibitor treatmentsimply ameliorates progression. In addition, blockade of theprorenin receptor leads to a reduction in activated prorenin+glomerular staining and renal angiotensin II levels. If confirmedby other groups, these observations give hope that such agentsmay one day be added to the treatment armamentarium for diabetes.See Takahashi et al., pages 2054–2061.
Angiotensin II Acidifies Urine by Stimulating Collecting Duct H+-ATPase
AngiotensinII contributes to the final acidification of urine through actionson the collecting duct, but how this occurs is unknown. Dr.Rothenberger and colleagues addressed this question using isolatedmouse outer medullary collecting duct cells. They report thatangiotensin II, signaling predominantly through the AT1 receptor,stimulates vacuolar H+-ATPase activity through a cascade involvingsmall G-proteins, phospholipase C, intracellular Ca2+, proteinkinase C isoforms, MAP kinases, and PI3 kinases. The group furthershows that the H+-ATPase B1 subunit is required for angiotensinII to exert its effect, the first H+-ATPase isoform-specificfunction identified in mammals. See Rothenberger et al., pages2085–2093.
Dietary Modifications Improve Survival in Mice with Deranged Mineral Metabolism
Fibroblastgrowth factor 23 (FGF23)-null mice are hyperphosphatemic, haveelevated 1,25(OH)2D levels, and die at an early age with extensivevascular calcifications. In this study by Dr. Stubbs and colleagues,dietary phosphate restriction completely resolves vascular calcificationsand significantly improves survival in FGF23-null mice despiteelevated 1,25(OH)2D and serum calcium levels. Conversely, normalizationof 1,25(OH)2D and serum calcium by dietary vitamin D restrictionalso improves survival despite continued hyperphosphatemia andvascular calcification. This report furthers our understandingof mineral metabolism, provides support for aggressive hyperphosphatemiatreatment, and suggests that supraphysiologic 1,25(OH)2D levelsmay have detrimental effects. See Stubbs et al., pages 2116–2124.
Human Growth Hormone Increases Lean Body Mass in Dialysis Patients
Humangrowth hormone reduces inflammation and tips the scales of proteinhomeostasis toward anabolism, two properties that suggest thathuman growth hormone may benefit the hemodialysis population.In a randomized placebo-controlled trial, Dr. Feldt-Rasmussenand colleagues report that human growth hormone treatment issafe and leads to a significant increase in lean body mass inadult hemodialysis patients. In addition, this proof of conceptstudy suggests that treatment may decrease cardiovascular riskand improve quality of life. See Feldt-Rasmussen et al., pages2161–2171.
Dietary Oxalate Has a Modest Effect on Stone Risk
Whereasthe contribution of urinary oxalate to the formation of calciumoxalate kidney stones is known, the contribution of dietaryoxalate is unknown. Drs. Taylor and Curhan prospectively followed>240,000 subjects in the Health Professionals Follow-Up Studyand the Nurses Health Studies I and II for a combined44 years to address this question. Their multivariate analysissuggests that, among men and older women, the association ofdietary oxalate and risk of symptomatic nephrolithiasis is modest,with no significant relationship observed in younger women.See Taylor and Curhan, pages 2198–2204.
CKD Is Associated with Poor Performance in Some Cognitive Tests
Cognitiveimpairment is common in the ESRD population, but it is not knownwhether it begins at earlier stages of chronic kidney disease(CKD). Dr. Hailpern and colleagues analyzed cross-sectionaldata from the National Health and Nutrition Examination SurveyIII, which included 4849 ethnically diverse subjects aged 20to 59 years who had participated in at least one cognitive test.In multivariate models, moderate CKD was associated with poorerperformance on tests of visual attention and learning/concentration,but was not significantly associated with visual-motor reactiontime. See Hailpern et al., pages 2205–2213.
Related Articles
Angiotensin II Stimulates Vacuolar H+-ATPase Activity in Renal Acid-Secretory Intercalated Cells from the Outer Medullary Collecting Duct
Florina Rothenberger, Ana Velic, Paul A. Stehberger, Jana Kovacikova, and Carsten A. Wagner
J. Am. Soc. Nephrol. 2007 18: 2085-2093.
[Abstract][Full Text][PDF]
Regression of Nephropathy Developed in Diabetes by (Pro)renin Receptor Blockade
Moderate Chronic Kidney Disease and Cognitive Function in Adults 20 to 59 Years of Age: Third National Health and Nutrition Examination Survey (NHANES III)
Susan M. Hailpern, Michal L. Melamed, Hillel W. Cohen, and Thomas H. Hostetter
J. Am. Soc. Nephrol. 2007 18: 2205-2213.
[Abstract][Full Text][PDF]
Growth Hormone Treatment during Hemodialysis in a Randomized Trial Improves Nutrition, Quality of Life, and Cardiovascular Risk
Bo Feldt-Rasmussen, Martin Lange, Wladyslaw Sulowicz, Uzi Gafter, Kar Neng Lai, Jonas Wiedemann, Jens Sandal Christiansen, Meguid El Nahas and the Adult Patients in Chronic Dialysis (APCD) Study Group
J. Am. Soc. Nephrol. 2007 18: 2161-2171.
[Abstract][Full Text][PDF]
Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice
Jason R. Stubbs, Shiguang Liu, Wen Tang, Jianping Zhou, Yong Wang, Xiaomei Yao, and L. Darryl Quarles
J. Am. Soc. Nephrol. 2007 18: 2116-2124.
[Abstract][Full Text][PDF]
B. I. Freedman, M. Bostrom, P. Daeihagh, and D. W. Bowden Genetic Factors in Diabetic Nephropathy
Clin. J. Am. Soc. Nephrol.,
November 1, 2007;
2(6):
1306 - 1316.
[Abstract][Full Text][PDF]